Predictors of Mortality in Cirrhotic Patients With Acute Kidney Injury
Clinical and Laboratory Predictors of Short-Term Mortality in Cirrhotic Patients With Acute Kidney Injury
Acute kidney injury (AKI) is a common and severe complication in patients with liver cirrhosis, significantly increasing the risk of short-term mortality. Early identification of clinical and laboratory predictors of mortality in these patients is crucial for risk stratification and optimizing clinical management.
This study aims to identify the key clinical parameters (such as the presence of ascites, hepatic encephalopathy, and hemodynamics) and laboratory markers (such as serum creatinine, bilirubin, albumin, sodium, and INR) that predict short-term mortality in cirrhotic patients presenting with AKI. The findings will assist clinicians in recognizing high-risk patients early and tailoring targeted therapeutic interventions .
연구 개요
상태
상세 설명
Cirrhosis-associated acute kidney injury (AKI) represents a major prognostic milestone in the clinical course of end-stage liver disease. While baseline scoring systems like the Model for End-Stage Liver Disease (MELD) and Child-Pugh score provide overall prognostic value, specific clinical and dynamic laboratory predictors are needed to refine short-term mortality risk assessment in the context of AKI.
Objectives:
- To evaluate the clinical presentation and laboratory parameters of cirrhotic patients at the time of AKI diagnosis.
- To determine independent clinical and laboratory factors associated with short-term mortality.
- To assess the predictive performance of clinical scoring systems in this specific cohort.
Methodology:
This observational study will enroll patients diagnosed with liver cirrhosis and AKI based on International Club of Ascites (ICA-AKI) criteria. Comprehensive clinical evaluations and laboratory investigations will be recorded at baseline/admission. Patients will be followed up for [30 / 90 days] to assess clinical outcomes, including survival, recovery of renal function, or mortality. Multivariate statistical analysis will be applied to identify independent mortality predictors.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: mohamed emad salah, MBBCh
- 전화번호: +201005127591
- 이메일: muhamed.emad19@icloud.com
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Adults aged ≥ 18 years.
- Hospitalized cirrhotic patients who develop AKI and mortality occurs within 30 days of the development of AKI
Exclusion Criteria:
- Patients younger than 18 years
- Patients with HIV infection.
- Patients with previous liver transplantation.
- Patients with incomplete clinical or laboratory data
- Patients with end-stage chronic kidney disease on maintenance dialysis.
- Patients with acute liver failure without underlying liver cirrhosis
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
Cirrhotic Patients
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Short-term mortality
기간: From hospital admission up to hospital discharge, an average of 2 weeks
|
Mortality among cirrhotic patients presenting with acute kidney injury
|
From hospital admission up to hospital discharge, an average of 2 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Serum creatinine associated with in-hospital mortality
기간: From hospital admission up to hospital discharge, an average of 2 weeks
|
Serum creatinine will be assessed at hospital admission and its association with in-hospital mortality will be evaluated.
|
From hospital admission up to hospital discharge, an average of 2 weeks
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .